Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. - Wikidata - awgldk - TriplyDB

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

http://www.wikidata.org/entity/Q39775786

about

Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair?Redox control of microglial function: molecular mechanisms and functional significance Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex Dietary Phytochemicals in Neuroimmunoaging: A New Therapeutic Possibility for Humans?The complexity of the Nrf2 pathway: beyond the antioxidant response Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection NRF2-regulation in brain health and disease: implication of cerebral inflammation Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1 Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.Towards translational therapies for multiple system atrophy Temporal and spatial dynamics of nrf2-antioxidant response elements mediated gene targets in cortex and hippocampus after controlled cortical impact traumatic brain injury in mice.Age-related retinopathy in NRF2-deficient mice.NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology.Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.Tolerance of neurite outgrowth to Rho kinase inhibitors decreased by cyclooxygenase-2 inhibitor.Role of the Keap1/Nrf2 pathway in neurodegenerative diseases.The endotoxin-induced neuroinflammation model of Parkinson's disease.Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia.The PTEN/NRF2 axis promotes human carcinogenesis Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism.A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model.Nrf2-ARE activator carnosic acid decreases mitochondrial dysfunction, oxidative damage and neuronal cytoskeletal degradation following traumatic brain injury in mice.Expression and contributions of TRPM7 and KCa2.3/SK3 channels to the increased migration and invasion of microglia in anti-inflammatory activation states The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide.Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis.Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease Sulforaphane induces Nrf2 target genes and attenuates inflammatory gene expression in microglia from brain of young adult and aged mice Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo.Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson's disease alpha-synuclein transgenic mice.

P2860

Q26824390-93DBC573-3570-4F36-AA04-C2A7AE004D45 Q26827634-757F6E74-A656-4C40-B788-D5DA02986262 Q27000279-7278C276-9CFE-460E-B862-7D4EA5C7AD70 Q27301885-64911BF2-8083-4BBC-8420-73F71691EFAE Q27689053-25B58BA3-8D8E-4698-B9A1-F2D16E392BD8 Q28075814-F1AA480F-E49B-4717-A5F4-C5B73198E1B3 Q28389296-4DAB849E-B57E-455C-9D52-7E4BAB767D6F Q28394732-02131C2C-5D41-4E02-A999-DA52D4949FDC Q28395641-248921A3-CF07-4758-8B28-5071CBD0D4F0 Q28396785-7966DCFE-8703-4408-AA7C-9FE9454ADEA0 Q28397785-CEF662E8-9D3B-4B89-8C75-DA52BD604E9C Q33646741-7961BD9A-D7A4-4ABB-9387-58F9F87E8354 Q33771694-BED02227-01C0-4880-829E-412CD4D78582 Q33797532-57D06536-9BC8-41CB-B8EC-FCBE91352103 Q33847548-D0F1DC4E-1D42-418D-BBAC-8296A23A3CC9 Q33894963-C99F6663-54B2-473B-9B2C-3B86DB681298 Q33900736-DE0A9487-4D3A-4191-9034-1D357DC974D4 Q34075866-F15FC153-A362-43DB-BE7D-F3F588B28F71 Q34358302-8C024ED8-AFDF-45C9-8682-670153B19031 Q34464138-CF5B63F3-A97E-4A96-9F2E-B0AF10BE77CD Q34557246-6700B13B-8A2F-472B-BCAE-B35BD4E4B547 Q34575719-1AC17E18-58F1-4587-9963-165EAF887B02 Q34579435-6E75B5CF-E247-4F92-8201-277EE72350D0 Q34612473-2DC94650-0064-4A16-8169-EB30E388497B Q35039225-97805687-492F-4236-9465-1621CA8CBDE8 Q35071145-C6545518-127D-41F2-9640-974368510F4C Q35229982-8332468E-6762-40C5-9030-35C5B5187F79 Q35624344-E6839F04-F5FA-4E65-AB4B-6255E851C9D5 Q35690505-FE4D5997-D1C0-499F-9C3B-BFAB9D088EFB Q35839143-64CEF713-4031-4E67-B5A3-56581A7CE050 Q36172880-15746C9C-9727-4925-9852-D4B3FCDFA1B6 Q36326535-720064E4-25C4-4FAE-9CB5-29818C68C815 Q36463773-D8ADE861-4D3E-4E8D-8FBA-E9B0BD734A44 Q36640417-861B5576-EB4F-487B-8786-A3A682167913 Q36674740-FADCC477-F4E5-4DD9-AAD5-9FCAC57C91C8 Q36732766-AC970535-9BF8-4DC8-9F81-C5003E9E662D Q36795890-C76694ED-AF7B-4946-BC10-2DFBFB42F911 Q37091371-4C50E34A-FD5C-4941-9AEF-89F3619B8640 Q37122279-39AED2B7-A6A7-4313-B5CA-28BEDB685063 Q37151427-5CED3FBF-6923-4560-8AFD-3DF14AB11F4F

P2860

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

http://www.wikidata.org/entity/Q39775786

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@en

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@nl

type

label

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@en

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@nl

prefLabel

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@en

Nrf2 regulates microglial dyna ...... erimental Parkinson's disease.

@nl

P1433

Q39775786-AF8D9448-BEC9-43C4-84D0-3B8E25776C27

P1476

Q39775786-50E877CE-402D-48F8-92EC-BC97C4D07CCD

P2093

Q39775786-07D079ED-E144-4B47-A531-16B0AB60A4EB

Q39775786-1EC14E02-336B-4365-B18A-C80B6F3FE580

Q39775786-7BBD4E90-8F91-4896-AD7A-CD9434573303

P2860

Q39775786-0E7FC0FC-8B8D-4B17-90B7-2F12222B1ADD

Q39775786-123C1D5A-93B4-4BB6-A12C-632CCB322DFC

Q39775786-13FE5B3E-2605-4529-8801-317FA3D8E685

Q39775786-22898089-F1B2-4242-B6B4-74FCD258B475

Q39775786-26F1B604-39C2-4C07-BD4F-EB83AAE84D0B

Q39775786-36402A8D-E542-4B09-8511-64A45FD7792B

Q39775786-3B08A0CD-8808-49C6-9ACB-FCEEF02A896F

Q39775786-4CB7BA93-399D-44D5-926E-BC49603A07F7

Q39775786-530F8D83-B188-4CD4-B88F-969A1B152DBC

Q39775786-53CA4A24-EF4A-412E-A2E8-825674AD12F4

P304

Q39775786-330F14EA-3B0B-476E-8D87-710A3DE1F40C

P31

Q39775786-B9F03600-E26D-41A5-8C42-8A81832FB378

P356

Q39775786-1045535B-18AD-42AB-A738-061171DECEE4

P433

Q39775786-AA6038CF-3096-47FF-9F5D-21B05F4F4DD4

P478

Q39775786-3A0EF58E-878E-41F7-836E-CCC1030F4D62

P50

Q39775786-0032279B-938A-4651-8032-0028A967052F

Q39775786-D4623A84-C3C4-49C6-BE93-DA26E451EEBB

Q39775786-E5A0BF66-2CD8-4ABA-922B-24316525A08D

P577

Q39775786-136EC98C-80CF-4CC1-A45A-F95A43F524B7

P698

Q39775786-DFCA517B-D19E-4DCC-A775-B55E38C0EFD9

P921

Q39775786-351B93B4-92CA-4796-B69F-64EFFA8B0B99

Q39775786-8f840177-7d3f-4fd6-883a-bd685627ea4a

Q39775786-F52380E2-4846-493B-A52A-61C82560AB71

P356

P1433

P1476

Nrf2 regulates microglial dyna ...... perimental Parkinson's disease

@en

P2093

Ana M Martín-Moreno

http://www.w3.org/2001/XMLSchema#string

Masayuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Nadia G Innamorato

http://www.w3.org/2001/XMLSchema#string

P2860

DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2

Exploring the full spectrum of macrophage activation

An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements

Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice

DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

Molecular pathways of neurodegeneration in Parkinson's disease

Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis.

Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD

Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.

P304

588-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GLIA.20947

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Cuadrado

María L de Ceballos

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19908287

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease